The team at Penn State has unveiled a pioneering 3D-printed bioelectronic system known as CaroFlex, designed to interface seamlessly with the carotid sinus artery. This bioelectronic interface offers a soft, stretchable, and biocompatible solution, markedly different from existing devices composed of rigid metals and plastics. By leveraging 3D printing technology and hydrogel-based materials, CaroFlex circumvents the limitations posed by conventional devices, such as mechanical mismatch, tissue damage, and instability caused by sutures traditionally used for device fixation.

At the core of CaroFlex’s design is the use of conductive hydrogel electrodes integrated with adhesive hydrogel films, which allow gentle yet effective electrical stimulation of baroreceptors located in the carotid sinus—a critical node for blood pressure regulation. Baroreceptors are specialized nerve endings that monitor arterial stretch, activating the baroreflex, a physiological mechanism that constrains or dilates arteries to stabilize blood pressure homeostasis. Through the precise modulation of these receptors via varied electrical frequencies, CaroFlex demonstrates the ability to recalibrate the body’s intrinsic pressure control system without invasive surgery or systemic drug exposure.

The development process involved meticulous characterization of the mechanical and electrical properties of CaroFlex. In vitro testing revealed the device’s extraordinary elasticity, capable of stretching over twice its initial length prior to mechanical failure, ensuring undisrupted function despite the dynamic movements of arterial tissues. Moreover, the adhesive hydrogel maintained robust and consistent adhesion to biological surfaces, even after prolonged storage exceeding six months, highlighting its practical durability for clinical applications.

A critical comparison with traditional platinum-based bioelectrodes underscored CaroFlex’s superior performance. While platinum electrodes often suffer from mechanical rigidity and poor tissue integration, leading to compromised electrical conduction and tissue damage, CaroFlex adhered more intimately to the tissues and ensured a stable, reliable electrical interface. This enhanced adhesion mitigates the need for suturing, a common source of complications in existing bioelectronic implants.

Translational relevance of this technology was evaluated through in vivo experiments in rodent models. Implanting CaroFlex onto the carotid sinus of rats and continuously monitoring their blood pressure revealed that four out of five tested electrical frequencies achieved a significant reduction in active blood pressure, averaging over a 15% decrease during a 10-minute stimulation period. Importantly, no adverse inflammatory or immune responses were detected after two weeks of implantation, attesting to the device’s biocompatibility and safety profile.

This novel approach underscores a paradigm shift in hypertension therapy, from systemic pharmaceutical management towards localized neuromodulation using soft, bioadhesive electronics. By targeting the baroreflex system through the carotid sinus, CaroFlex offers a minimally invasive, precisely controllable, and patient-friendly alternative, particularly for individuals with drug-resistant hypertension who face limited treatment options.

Beyond its therapeutic potential, CaroFlex exemplifies the advantages of 3D printing technology in bioelectronics. The additive manufacturing process allows rapid prototyping, customization, and scalable production while reducing manufacturing costs and material waste. This flexibility accelerates the path from bench to bedside, facilitating iterative optimization, adaptation to various anatomical needs, and potential mass clinical deployment.

The research team, led by Tao Zhou, a rising expert in engineering science and mechanics at Penn State, is actively refining CaroFlex’s stimulation parameters and exploring avenues to scale up the technology for human clinical trials. The vision is to establish CaroFlex as a clinically viable, suture-free, bioadhesive bioelectronic interface that can sustainably regulate blood pressure, improve cardiovascular outcomes, and enhance patients’ quality of life.

This interdisciplinary endeavor unites expertise from biomedical engineering, materials science, neural engineering, and clinical medicine, with contributions from doctoral candidates and faculty across Penn State and the University of Michigan. The work received critical financial support from the National Institutes of Health and the U.S. National Science Foundation, underscoring the federal commitment to fostering cutting-edge medical innovation.

The emergence of CaroFlex not only represents a formidable advance in managing a global health burden but also illuminates the vast potential of biointegrated electronics to address complex physiological disorders. As 3D printing technologies and hydrogel bioelectronics continue to evolve, the horizon expands for new devices that harmonize with the body’s natural systems, heralding a new era in personalized and precision medicine.

Subject of Research: Animals

Article Title: 3D printable suture-free bioadhesive electronic interface for hypertension therapy

News Publication Date: 5-May-2026

Web References:

• DOI: 10.1016/j.device.2026.101150
• Tao Zhou’s Profile: Penn State College of Engineering
• Hypertension Prevalence Data: Million Hearts Initiative

Image Credits: Provided by Tao Zhou

Keywords

Hypertension, Bioelectronics, Baroreflex, Carotid sinus, 3D printing, Hydrogel electrodes, Neuromodulation, Cardiovascular therapy, Drug-resistant hypertension, Biocompatible materials, Biomedical engineering, Neural engineering

The soft bladder-machine interface is designed to seamlessly integrate with the dynamic and highly flexible tissue of the bladder, a critical factor that distinguishes this innovation from conventional rigid devices. Traditional neuroprosthetics often struggle to maintain stable contact and effective functionality when interacting with organs subject to continuous movement and deformation. The use of soft, stretchable materials in this interface addresses these issues, allowing for biocompatible implantation that conforms closely to the bladder’s surface, reducing tissue irritation and improving long-term operational stability.

Underpinning this technology is an advanced neuroelectronic system capable of bidirectional communication with the peripheral nervous system. This interface not only records neural signals associated with bladder filling and voiding but also delivers targeted electrical stimulation to restore and modulate bladder function. Such sophistication enables precise control over bladder activities, potentially alleviating symptoms like incontinence and urinary retention that drastically impact daily living for millions of patients worldwide.

The development process involved integrating soft microelectrode arrays with wireless communication modules embedded within an ultra-flexible substrate. The electrode arrays capture subtle neural activities with high fidelity, while the wireless component facilitates external programming and data monitoring without impeding patient mobility. The entire system is powered by an innovative, miniaturized energy-harvesting or battery mechanism tailored for long-term implantation, ensuring the device remains operational without frequent interventions.

A striking feature of this bladder-machine interface is its adaptive learning algorithm. Drawing from state-of-the-art machine learning, the system interprets complex neural patterns, dynamically adjusting stimulation parameters in response to changing physiological conditions. This personalized approach to neuromodulation represents a paradigm shift in treating neurogenic bladder dysfunction, moving beyond one-size-fits-all therapies to patient-specific solutions that evolve over time.

Extensive preclinical trials have demonstrated the interface’s ability to restore controlled bladder voiding in animal models with induced neural injury. The researchers reported significant improvements in urinary function, with the soft interface maintaining intimate contact with the bladder even during cycles of filling and emptying, proof of its mechanical resilience and biocompatibility. These promising results pave the way for forthcoming clinical trials aimed at verifying safety, efficacy, and long-term outcomes in human patients.

One of the compelling advantages of this system lies in its minimally invasive implantation method. The device’s softness and flexibility allow for implantation via laparoscopic procedures, thereby reducing surgical trauma and accelerating patient recovery. Moreover, the low profile of the interface minimizes risks of infection and foreign body sensation, common complications associated with implanted prosthetic devices.

The team also focused on real-time data acquisition and processing. Continuous monitoring of bladder status and neural activity provides valuable insights for patients and clinicians, enabling finer adjustments of the device and enhancing overall therapeutic effectiveness. This data-driven feedback loop supports proactive management of bladder dysfunction, potentially preventing complications such as urinary tract infections and bladder overdistension.

Importantly, this technology aligns with the broader trend of integrating bioelectronic medicine into therapeutic regimens. By interfacing electronics directly with neural circuits, the device exemplifies how responsive, implantable systems can replace or supplement pharmacological treatments, which often have systemic side effects. The soft bladder-machine interface, therefore, not only improves physiological function but also heralds a future where personalized electronic therapeutics become a mainstay in chronic disease management.

The potential impact of this research extends beyond neurogenic bladder dysfunction. The principles of soft electronics, wireless communication, and machine learning integration can be adapted to other organ systems affected by neurological impairments, such as bowel, respiratory, or cardiac dysfunctions. This versatility underscores the transformative nature of the technology and its capacity to broaden therapeutic horizons.

As with any emerging biomedical device, challenges remain before widespread clinical deployment. Long-term biostability, immune response mitigation, and device integration with standard medical practices require further investigation. Additionally, ethical considerations surrounding neural modulation and patient autonomy must be carefully addressed to ensure responsible application of this technology.

Nevertheless, the implantable soft bladder-machine interface marks a monumental step forward in neuroprosthetic design. Its synthesis of flexible materials, advanced electronics, and intelligent algorithms exemplifies the future of medical devices: minimally invasive, highly adaptive, and deeply integrated with human physiology. For patients suffering from neurogenic bladder dysfunction, this innovation represents renewed hope for regaining autonomy and enhancing life quality.

This breakthrough is expected to catalyze further research into soft bioelectronic interfaces, inspiring new applications and accelerating the convergence of engineering, neuroscience, and medicine. As clinical trials progress, the medical community eagerly awaits confirmation of its potential to set new standards in treating bladder dysfunction and beyond.

In conclusion, the work by Li, H., Wang, S., Yu, Q., and colleagues exemplifies the remarkable advancements in bioelectronic medicine through the development of an implantable, soft bladder-machine interface. Their pioneering contribution offers a comprehensive solution to a challenging medical problem, combining multidisciplinary expertise to deliver a device that is as functional as it is innovative. As this technology moves closer to clinical reality, it not only promises improved therapeutic outcomes but also highlights the power of technology-driven personalized medicine in addressing complex neurogenic disorders.

Subject of Research: Development of an implantable soft bladder-machine interface aimed at treating neurogenic bladder dysfunction through advanced bioelectronic and neural engineering approaches.

Article Title: Implantable soft bladder-machine interface for neurogenic bladder dysfunction

Article References:
Li, H., Wang, S., Yu, Q. et al. Implantable soft bladder-machine interface for neurogenic bladder dysfunction. Nat Commun 17, 2458 (2026). https://doi.org/10.1038/s41467-026-70680-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-70680-0